MLL Gene Rearrangement in Acute Myelogenous Leukemia After Exposure to Tegafur/Uracil
- 62 Downloads
We report a case of acute myelogenous leukemia (AML) withMLL (myeloid-lymphoid leukemia or mixed-lineage leukemia) gene rearrangement after exposure to tegafur/uracil. Cytogenetic and clinical findings in this patient: t(11;17) (q23;q25), AML-M4 morphology, development of AML within a short latent period after first exposure to tegafur/uracil, and good response to remission induction chemotherapy but short remission duration, have been considered typical features of therapy-related acute myelogenous leukemia (t-AML) after exposure to topoisomerase II—targeting agents. This case report suggests that t-AML may develop after exposure to tegafur/uracil and thatMLL gene rearrangement may not necessarily be specific to t-AML after exposure to topoisomerase II—targeting agents.
Key wordsTherapy-related acute myelogenous leukemia Tegafur/uracil Fluorouracil MLL gene rearrangement t(11,17) (q23,q25)
Unable to display preview. Download preview PDF.
- 1.Le Beau MM, Albain KS, Larson RA, et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7.J Clin Oncol. 1986;4:325–345.CrossRefPubMedGoogle Scholar
- 3.Pedersen-Bjergaard J, Philip P, Larsen SO, et al. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series.Leukemia. 1993;7:1975–1986.PubMedPubMedCentralGoogle Scholar
- 4.Gill Super HJ, McCabe NR, Thirman MJ, et al. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II.Blood. 1993;82:3705–3711.Google Scholar
- 15.Shimano S, Murayama K, Katahira H, Tsuchiya J. A retrospective study of acute myelogenous leukemia and myelodysplastic syndrome cases—clinical and hematological findings [in Japanese].Jpn J Cancer Clin. 1994;40:175–179.Google Scholar
- 16.Komatsu T, Yamazaki H, Shimada N, Nakajima M, Yokoi T. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver micro-somes.Drug Metab Dispos. 2000;28:1457–1463.Google Scholar
- 17.Heidelberger C, Danenberg PV, Moran RG. Fluorinated pyrimidines and their nucleosides.Adv Enzymol Relat Areas Mol Biol. 1983;54:58–119.Google Scholar
- 19.Broeker PLS, Super HG, Thirman MJ et al. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites.Blood. 1996;87:1912–1922.PubMedPubMedCentralGoogle Scholar
- 25.Megonigal MD, Rappaport EF, Jones DH, et al. T(11;22) (q23;q11.2) in acute myeloid leukemia of infant twins fuses MLL with hCDCrel, a cell division cycle gene in the genomic region of deletion in DiGeorge and velocardiofacial syndromes.Proc Natl Acad Sci U S A. 1998;95:6413–6418.CrossRefPubMedPubMedCentralGoogle Scholar